Advertisement
A vs DHR
Which Stock Would AI Choose? Agilent Technologies (A) vs. Danaher (DHR) Stock Comparison
Key Takeaways
- Agilent Technologies (A) reported stronger recent quarterly revenue growth of approximately 10% year-over-year compared to Danaher (DHR)’s more moderate biotechnology-driven expansion.
- Both companies operate in the life sciences sector, with A focused on analytical instruments and DHR maintaining a broader portfolio including diagnostics and biotechnology solutions.
- Recent market activity shows A benefiting from product launches and acquisitions, while DHR has completed the Masimo acquisition and raised full-year guidance amid segment-specific strength.
- Valuation metrics indicate A trading at relatively lower price-to-earnings multiples than DHR based on forward estimates.
- Year-to-date performance has been mixed, with DHR showing positive returns around 16% while A has experienced modest declines or flat results amid sector volatility.
- Market sentiment reflects ongoing focus on earnings visibility and order trends for both stocks in a stable but selective healthcare environment.
Introduction
Agilent Technologies (A) and Danaher (DHR) represent two prominent players in the life sciences and diagnostics space, making them relevant for comparison among investors and traders seeking exposure to healthcare innovation and analytical tools. This analysis examines their business models, recent performance trends, and relative positioning to assist those evaluating sector peers for portfolio allocation or short-term trading strategies. Market participants monitoring earnings momentum, acquisition activity, and valuation disparities may find this overview particularly useful for understanding trade-offs in a competitive industry landscape.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies (A) specializes in analytical instrumentation, reagents, and software for life sciences, diagnostics, and applied markets. In recent weeks, the stock has shown resilience following better-than-expected revenue results, with sales rising about 10% year-over-year to $1.84 billion in the most recent reported quarter. Key influences include new product introductions such as AI-powered cell imaging software and HPLC column expansions, alongside the completion of the Biocare Medical acquisition. Sentiment has been supported by analyst upgrades and raised price targets, though broader market conditions and sector rotation have contributed to modest price fluctuations around the $129 level.
Danaher (DHR) Overview and Recent Performance
Danaher (DHR) operates a diversified portfolio spanning life sciences, diagnostics, and environmental solutions, with particular emphasis on its biotechnology segment. Recent market activity highlights continued growth in biotechnology revenues, up approximately 7% year-over-year, alongside the closure of the Masimo acquisition. The company has also lifted its full-year earnings outlook despite some revenue variability in other areas. Performance has reflected these catalysts, with shares trading near $191 amid ongoing analyst attention and sector sentiment, though the stock has faced periodic pressure from macroeconomic factors and peer comparisons.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from hundreds available across thousands of tickers. Only the most suitable bots for prevailing market conditions earn placement in this section, showcasing varied trading styles, strategies, timeframes, and performance statistics. Available bots demonstrate a wide range of outcomes, with many achieving positive returns over different periods depending on their specific parameters and ticker focus. This resource provides traders with data-driven options to explore automated strategies aligned with individual risk preferences and market views.
Head-to-Head Comparison
Agilent Technologies (A) maintains a specialized focus on precision instrumentation and biopharma workflows, contrasting with Danaher (DHR)’s broader conglomerate structure that includes diagnostics and environmental applications. Growth drivers differ accordingly, with A emphasizing recent product innovations and targeted acquisitions, while DHR benefits from biotechnology segment stability and larger-scale deals such as Masimo. Recent momentum favors A’s earnings beats and new launches, whereas DHR has demonstrated guidance raises amid acquisition integration. Risk factors for both include sector cyclicality and supply chain dependencies, though DHR’s diversification may offer relative stability. Market sentiment positions A at potentially more attractive valuations, creating trade-offs for investors prioritizing growth consistency versus portfolio breadth.
Tickeron AI Verdict
Based on observable factors including more consistent recent revenue growth, lower valuation multiples, and upcoming earnings visibility, Tickeron’s AI models currently assign a modestly higher probability of favorable relative performance to Agilent Technologies (A) versus Danaher (DHR) over the near term, subject to confirmation of order trends and broader sector stability.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a StrongBuy and DHR is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 1 FA rating(s) are green whileDHR’s FA Score has 1 green FA rating(s).
- A’s FA Score: 1 green, 4 red.
- DHR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 2 TA indicator(s) are bullish while DHR’s TA Score has 6 bullish TA indicator(s).
- A’s TA Score: 2 bullish, 5 bearish.
- DHR’s TA Score: 6 bullish, 4 bearish.
Price Growth
A (@Medical Specialties) experienced а +2.75% price change this week, while DHR (@Medical Specialties) price change was +0.57% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.81%. For the same industry, the average monthly price growth was +11.88%, and the average quarterly price growth was +7.07%.
Reported Earning Dates
A is expected to report earnings on Aug 18, 2026.
DHR is expected to report earnings on Jul 21, 2026.
Industries' Descriptions
@Medical Specialties (-0.81% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| A | DHR | A / DHR | |
| Capitalization | 37.9B | 141B | 27% |
| EBITDA | 1.96B | 7.08B | 28% |
| Gain YTD | -0.716 | -12.682 | 6% |
| P/E Ratio | 26.97 | 38.58 | 70% |
| Revenue | 7.23B | 24.8B | 29% |
| Total Cash | N/A | N/A | - |
| Total Debt | 3.35B | 18.5B | 18% |
A | DHR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 29 | 30 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 44 | 80 | |
PRICE GROWTH RATING 1..100 | 51 | 57 | |
P/E GROWTH RATING 1..100 | 63 | 54 | |
SEASONALITY SCORE 1..100 | 85 | 19 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (8) in the Biotechnology industry is in the same range as DHR (10) in the Medical Specialties industry. This means that A’s stock grew similarly to DHR’s over the last 12 months.
A's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DHR (100) in the Medical Specialties industry. This means that A’s stock grew similarly to DHR’s over the last 12 months.
A's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for DHR (80) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than DHR’s over the last 12 months.
A's Price Growth Rating (51) in the Biotechnology industry is in the same range as DHR (57) in the Medical Specialties industry. This means that A’s stock grew similarly to DHR’s over the last 12 months.
DHR's P/E Growth Rating (54) in the Medical Specialties industry is in the same range as A (63) in the Biotechnology industry. This means that DHR’s stock grew similarly to A’s over the last 12 months.
| A | DHR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 65% | 2 days ago 47% |
| Stochastic ODDS (%) | 2 days ago 64% | 2 days ago 71% |
| Momentum ODDS (%) | 2 days ago 65% | 2 days ago 57% |
| MACD ODDS (%) | 2 days ago 68% | 2 days ago 64% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 55% |
| TrendMonth ODDS (%) | 2 days ago 57% | 2 days ago 53% |
| Advances ODDS (%) | 2 days ago 60% | 2 days ago 54% |
| Declines ODDS (%) | 6 days ago 63% | 12 days ago 61% |
| BollingerBands ODDS (%) | 2 days ago 64% | 2 days ago 61% |
| Aroon ODDS (%) | N/A | 2 days ago 48% |
Advertisement
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | +1.57% | ||
| TMO - DHR | 77% Closely correlated | +0.45% | ||
| A - DHR | 73% Closely correlated | +0.52% | ||
| RGEN - DHR | 68% Closely correlated | +0.21% | ||
| RVTY - DHR | 65% Loosely correlated | -0.58% | ||
| MTD - DHR | 64% Loosely correlated | +0.63% | ||
More | ||||